Janux Therapeutics, Inc. (JANX) stock
JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3031% below fair value
$11.37−0.13 (-1.09%)
Close on Nov 13, 2026Market cap $695.13MP/E –Yield –
Janux Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Janux Therapeutics's enterprise value was -$214.16M on Nov 11, 2026, against $1.06B a year earlier. Over the last 5 years it ranged from -$214.16M to $2.29B, with a median of $239.54M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$214.16M | – |
| 2025 | Dec 31, 2025 | -$159.29M | -107.4% |
| 2024 | Dec 31, 2024 | $2.14B | +1373.7% |
| 2023 | Dec 29, 2023 | $145.49M | -30.2% |
| 2022 | Dec 30, 2022 | $208.46M | -50.9% |
| 2021 | Dec 31, 2021 | $424.82M | – |
See a number that looks wrong?